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Reversal of TREM-1 ectodomain shedding and
improved bacterial clearance by intranasal
metalloproteinase inhibitors
GWeiss1,3, C Lai1,3, ME Fife2, AM Grabiec2, B Tildy1, RJ Snelgrove1, G Xin1, CM Lloyd1 and T Hussell1,2
Triggering receptor expressed on myeloid cells-1 (TREM-1) is expressed on neutrophils and monocyte/macrophages
and amplifies Toll-like receptor-mediated inflammation during infection. TREM-1 also exists in an antagonistic soluble
form (sTREM-1) that has been used as a peripheral biomarker in sepsis, though the mechanisms of its release are not
entirely clear. The requirement of TREM-1 in single microbial infections is controversial, with some studies showing a
protective role and others a contribution to immunopathology. Furthermore, the role ofmembrane-bound and sTREM-1
in polygenic infections is currently unknown. In a mouse co-infection model where preceding viral infection greatly
enhances bacteria co-infection, we now determine a mechanisms for the striking increase in sTREM-1 and the loss of
TREM-1 on surface of neutrophils. We identified a matrix metalloproteinase (MMP)-9 cleavage site in TREM-1 and that
the increase of MMP-9 in bronchoalveolar lavage fluid mirrors sTREM-1 release. In vitro studies with neutrophils and
MMP-9 and the reduction of sTREM-1 in vivo after MMP-9 inhibition verifies that this enzyme cleaves TREM-1.
Intriguingly, MMP-9 inhibition significantly reduces bacterial load and ensuing immunopathology in a co-infection
model. This highlights MMP-9 inhibition as a potential therapeutic via blocking cleavage of TREM-1.
INTRODUCTION
Bacterial super-infections often follow pulmonary virus
infection and are a major cause of excess morbidity and
mortality.1 Enhanced disease is due to a combination of
excessive host immune responses and an exponential increase
in bacterial replication that invades the lung and disseminates
to distant organs.2 Membrane-bound pathogen recognition
receptors on innate immune cells respond either alone or in
combination to allow diversification of the early immune
response. Co-operation between receptors draws in a variety of
signaling cascades that shape an appropriate response, or in the
case of some co-receptors, timely termination of inflammation.
The triggering receptors expressed on myeloid cells (TREM)
family either amplifies (TREM-1) or dampens (TREM-2)
inflammation.3 TREM-1 amplifies the inflammatory response
to Toll-like receptor signaling by recruiting the transmembrane
adapter molecule DAP12, which recruits the tyrosine kinase
Syk and leads to the activation of PI3K and MAPK.4 TREM-1
signaling also enhances NF-kB induced cytokine production in
dendritic cells via caspase-recruitment domain protein
(CARD)-95 and downregulates suppressor of cytokine signal-
ing-1 (SOCS-1) by inducing the expression of miR-155 in
macrophages and lungs of mice treated with LPS.6
Like many membrane bound receptors, TREM-1 also exists
in soluble form (sTREM-1). Although the function of sTREM-1
is unknown, it is likely to negatively regulatemembrane TREM-
1 receptor signaling through competition with the ligand(s).
sTREM-1 is under investigation as a biomarker in a variety of
infectious and non-infectious inflammatory conditions and is
detected in the bronchoalveolar lavage (BAL) fluid in
pneumonia7 and in the serum8,9 and urine10 of septic patients.
It is a marker of neonatal sepsis11 and predicts shock and
death.12 sTREM-1 and its gene polymorphisms are also
associated with sepsis prognosis13 and high sTREM-1 is
predictive of Systemic Inflammatory Response Syndrome
(SIRS)14 after surgery. TREM-1 and its soluble form are
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therefore potential diagnostic markers for infectious and
chronic inflammatory diseases and also potential future targets
for therapeutic manipulation.15,16 In order for sTREM-1 to be a
reliable marker of disease, a greater understanding of the cells
relevant to its release and mechanisms of its cleavage are
required. Furthermore, the long term impact of reducing
TREM-1 cleavage into the soluble form is currently unknown.
Secondary bacterial infections are a consequence of many
lung inflammatory diseases and arise due to defective
microbicidal responses in the remodeled airspaces.17 We
reasoned that the release of sTREM-1 is at least partly
responsible for impaired innate immune responses to bacteria
following influenza virus infection. We now report a matrix
metalloproteinase (MMP)-9 cleavage site within the TREM-1
sequence and demonstrate an in vivo correlation between
MMP-9 expression, the appearance of sTREM-1 in airway
lavage and neutrophil recruitment during pulmonary influenza
infection. This correlation is amplified in influenza virus/
bacterial super-infectedmice. Inhibition ofMMP-2/9 decreases
sTREM-1 and restores membrane-bound TREM-1 and anti-
bacterial immunity that prevents mortality following bacterial
superinfection. Although cleavage of immune stimulatory
receptors such as TREM-1 is an efficient means to curtail
inflammatory responses, it may have deleterious effects if the
pathogen has not been completely cleared.MMP-9 is raised in a
variety of pathologies associated with infectious complications.
We therefore conclude that inhibition of MMP-9 and TREM-1
cleavage represents novel therapeutic targets for the alleviation
of secondary bacterial pneumonia.
RESULTS
Influenza infection increases susceptibility to
Streptococcus pneumoniae superinfection
The murine model of bacterial superinfection following
influenza virus is well established with high reproducibility.18
Similar to prior studies, we show that uninfected mice gain
weight whereas intranasal influenza PR8 (H1N1) virus
infection causes substantial weight loss, peaking on day 7
after which they begin to recover (Figure 1a). Phosphate-
buffered saline (PBS) mock-infected mice administered 106
colony-forming unit (CFU) S. pneumoniae (Strep) intranasally
on day 7 did not lose weight and were similar to PBS alone
controls. However, intranasal infection with S. pneumoniae 7
days after influenza infection (PR8þ Strep) caused extensive
weight loss and the mice had to be killed. Co-infection was
accompanied by enhanced total cells in the BAL (Figure 1b)
and lung (Figure 1c), enhanced neutrophilia (Figure 1d),
elevated levels of tumor necrosis factor (TNF)-a (Figure 1e)
and exponentially higher bacterial loads in the BAL (Figure 1f),
lung (Figure 1g) and blood (Figure 1h) of co-infected mice.
Excessive release of MMP-9 and sTREM-1 during
secondary bacterial superinfection
We next determined the expression of sTREM-1, TREM-1 and
MMP-9 in our murine model of bacterial superinfection
following influenza virus. sTREM-1 levels in the BAL of PBS
control mice were very low, significantly increased in mice
infected with influenza alone and S. pneumoniae alone, but
were strongly elevated in co-infected mice (Figure 2a). A
similar pattern, though at lower concentration, was observed
measuring sTREM-1 in the serum (Figure 2b). MMP-9
expression in the BAL followed the same pattern with an
average 12- and 9-fold increase in co-infected mice compared
with those infected with influenza or S. pneumoniae alone,
respectively (Figure 2c). The correlation between MMP-9 and
sTREM-1 by Spearman rank test was highly significant
(R¼ 0.755, Po0.0001; Figure 2d).
As it has been suggested that sTREM-1 is generated via
cleavage of membrane-bound TREM-1 from the cell surface,19
and the co-infection model recruits a large number of
neutrophils that express it, we analyzed whether there is a
correlation between membrane-anchored TREM-1 on neu-
trophils and the release of sTREM-1 in the BAL. Both PBS
control and influenza infected mice expressed high levels of
TREM-1 on lung neutrophils (24% and 22%, respectively) and
displayed low levels of sTREM-1 in the BAL (Figure 2e). By
contrast bacterial infection alone, and especially following
influenza infection, reduced membrane-bound TREM-1 on
neutrophils and increased sTREM-1. This result was also
obtained applying total neutrophil numbers (Figure 2f). Thus,
it is indicated that the balance of membrane bound TREM-1
versus sTREM-1 is altered during inflammation of the lung,
which may lead to inefficient clearance of bacteria, resulting in
systemic dissemination and mortality.
Trem-1 contributes to neutrophil degranulation
Neutrophils constitute the main cellular defence against
S. pneumoniae.20 At the site of infection they phagocytose
bacteria that are killed by reactive oxygen species21,22 and serine
proteases cathepsin G, elastase and proteinase 3 released from
intracellular granules.23 Neutrophils also express pattern-
recognition receptors to sense and respond to pathogens.24
The function of TREM-1, and the impact of sTREM-1,
however, is currently unknown. We therefore purified
neutrophils from bone marrow and cultured them with LPS
in the presence of a TREM-1 agonist antibody or an
antagonistic TREM-1 peptide (LP17). Agonism of TREM-1
had no effect on phagocytosis of bacterial particles and ROS
production (data not shown), but enhanced degranulation,
which is reflected by the upregulation of CD63 (Figure 3a), and
CD11b expression (Figure 3b) whereas LP17 had the opposite
effect (Figure 3c,d). Thus TREM-1 potentiates certain aspects
of neutrophil anti-bacterial immunity.
Inhibition of MMP-2/9 prevents bacterial infiltration and the
proinflammatory response during secondary bacterial
superinfection
The TREM-1 sequence (MRKAGLWGLL CVFFVSEVKA
AIVLEEERTD LVEQTLTVKCPFNIMKYAN SQKAWQR-
LPD GKEPLTLVVT QRPFTRPSEV HMGKFTLKHD PSEA-
MLQVQM TDLQVTDSGL YRCVIYHPPN DPVVLFHPVR
LVVTKGSSDVFTPVIIPITR ITERPILITT KYSPSDTTTT
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RSLPKPTAVV SSPGLGVTII NGTDADSVST SSVTISVICG
IISKSLVFII LFIVTKRTFG) contains an MMP-9 cleavage site
(underlined). The possible sequence for an MMP-9 cleavage
site is P-X-X-H-T, where X is any amino acid and H is
hydrophobic.
To formally prove that MMP-9 causes the cleavage of
membrane-bound TREM-1, we incubated murine bone-
marrow-derived neutrophils with unactivated MMP-9 or
AMPA activated MMP-9 (as described by Marcy AL
et al25). Stimulation of bone-marrow-derived neutrophils with
activated MMP-9 reduced the expression of membrane-bound
TREM-1 and increased the levels of sTREM-1 compared with
unactivated MMP-9 (Figure 4a).
We next infected mice intranasally (i.n.) with influenza virus
strain PR8 and with S. pneumoniae on day 7. One co-infected
group was treated with an MMP-2/9 inhibitor i.n. on day 6
and day 7, whereas the other group received vehicle only. Mice
were sacrificed on day 8 (Figure 4b). The activation status of
MMP-9 was assessed by zymography in the BAL of influenza
and S. pneumoniae infected mice administered the MMP-2/9
inhibitor and compared with co-infected mice that received
vehicle only (Figure 4c). Co-infected mice showed strong
activity of MMP-9, which was substantially reduced upon
inhibitor treatment. Levels of sTREM-1 in BAL (Figure 4d) and
serum (Figure 4e) andMMP-9 protein levels in BAL (Figure4f)
and serum (Figure 4g) were significantly suppressed in the
inhibitor treated group. The activity (data not shown) and
expression (Figure 4h) of MMP-2 in the BAL was not affected
by the MMP-2/9 inhibitor, though this is likely to reflect
the very low levels found in this model compared with MMP-9
(data not shown). The correlation of sTREM-1 (Figure 4i)
with CFU was significant by Spearman Rank test (R¼ 0.744;
P¼ 0.002). However, similar to the correlation between CFU
and MMP-9 levels (Figure 4j), a certain threshold of bacteria
had to be present in order for sTREM-1 to increase. In both
cases this threshold appeared to be above 106 CFU per ml
(Figure 4i,j). Our results indicate that inhibition of MMP-2/9
reduces the release of TREM-1 in vivo.
Inhibition of MMP-2/9 increases the expression of TREM-1
on neutrophils in the lung during secondary bacterial
superinfection
A decrease in sTREM-1 could reflect a reduction in recruited
neutrophils rather than a decrease in sTREM-1 release. During
infection neutrophils are the main cellular source of MMP-9.26
As one role of MMP-9 is to cleave IL-8,27 (mouse homolog
KC),28 to form a more potent neutrophil chemoattractant we
next determined the impact of MMP-2/9 inhibition on cell
recruitment. Both vehicle and MMP-2/9 inhibitor treatment of
co-infected mice displayed equivalent airway (Figure 5a) and
only partially reduced lung (Figure 5b) cellularity. Importantly,
expression of TREM-1 onneutrophils was significantly higher in
BAL (Figure 5c,d) and lung (Figure 5e,f) of mice treated with
the MMP-2/9 inhibitor compared with the control group.
Figure 1 Influenza infection increases susceptibility to Streptococcus pneumoniae superinfection. BALB/c mice were infected with 7 plaque-forming
units (PFU) of PR8 influenza A virus, followed by 106 CFU S. pneumoniae on day 7 and analyzed 24 h post-S. pneumoniae infection (PR8þStrep).
Phosphate-buffered saline (PBS) mice, mice infected with influenza alone (PR8) and S. pneumoniae (Strep) alone were used as a control. Body weight
was measured daily and is expressed as percentage of original body mass (a). Total live cells in bronchoalveolar lavage (BAL) (b) and lung (c) was
determined by trypan blue exclusion. Neutrophils were identified by flow cytometry (d). Airway levels of tumor necrosis factor (TNF)-a (e) was determined
by enzyme-linked immunosorbent assay (ELISA). Viable bacterial colony-forming units (CFU) recovered from the BAL (f), lung tissue (g) and peripheral
blood (h) were enumerated by counting colonies on agar. Data are expressed as mean±s.e.m., n¼6–10 mice per group from two independent
experiments. Statistical significance was determined by Mann–Whitney U-test between relevant groups, **Po0.01, ***Po0.001.
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Administration of the MMP-2/9 inhibitor increased the
expression of TREM-1 on neutrophils in the BAL 4.3-fold
and in the lung 4.5-fold. A similar result was obtained for total
numbers of lung neutrophils where membrane-bound
TREM-1 was restored to pre-infection levels (Figure 5f).
Comparison of the release of sTREM-1 with membrane-
bound TREM-1 revealed that high amounts of sTREM-1
correlated with low expression of TREM-1 on neutrophils in
BAL (Figure 5g) and lung (Figure 5h). Thus, MMP-9
contributes to bacterial super-infection by cleaving
membrane-bound TREM-1, preventing the timely removal of
the bacterium from the influenza infected lung.
Figure 2 Excessive release of matrix metalloproteinase (MMP)-9 and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) during
secondary bacterial superinfection. BALB/c mice were infected with 7 plaque-forming units (PFU) of PR8 influenza A virus, followed by 106 PFU S.
pneumoniaeonday7andanalyzed 24 hpost-S. pneumoniae infection (PR8þStrep).Control groups asperFigure 1. (a) Expression of soluble triggering
receptor expressed on myeloid cells-1 (sTREM-1) in bronchoalveolar lavage (BAL) and (b) serum and (c) Matrix metalloproteinase (MMP)-9 in BAL
determined by enzyme-linked immunosorbent assay (ELISA). Spearman Rank correlation between BAL MMP-9 and sTREM (d, each point represents
an individualmouse). sTREM-1 (gray bars)measuredbyELISAcomparedwith (e) percentage of neutrophils or (f) total neutrophils expressingTREM-1þ
(&) in the lung measured by FCM. Naive, uninfected mice were analyzed as a control (phosphate-buffered saline (PBS)). Data are expressed as
mean±s.e.m., n¼ 6–10 mice from two independent experiments. Statistical significance was determined by Mann–Whitney U-test between relevant
groups, *Po0.05, **Po0.01, ***Po0.001.
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Inhibition ofMMP-2/9 reduces the expressionofMMP-9 and
sTREM-1 during secondary bacterial superinfection
As our results show that secondary bacterial superinfection
following influenza results in excessive release of MMP-9 and
sTREM-1, we next addressed whether inhibition of MMP-9
in vivo has an impact on disease outcome. As our results show
that secondary bacterial superinfection following influenza
results in excessive release of MMP-9 and sTREM-1, we next
addressed whether inhibition of MMP-9 in vivo has an impact
on disease outcome using the MMP-2/9 inhibitor co-infection
model infection model described in Figure 4b. No difference
in weight loss was observed in the inhibitor treated mice
compared with the PR8 influenza and S. pneumoniae infected
control mice administered vehicle only (Figure 6a). As demon-
strated previously, infection of mice with S. pneumoniae 7 days
post influenza leads to a high bacterial load in the airway, lung
and blood (Figure 1f-h). However, treatment with theMMP-2/
9 inhibitor significantly reduced bacterial titers in the BAL
(Figure 6b) and lung (Figure 6c) and, remarkably, completely
prevented sepsis (Figure 6d). In contrast to our co-infected
control group displaying a high bacterial load (9 107 CFU per
ml), no bacteria were detected in the blood of mice treated with
the inhibitor. We also observed a significant reduction in
the airway proinflammatory cytokines interleukin (IL)-6
(Figure 6e), IL-1a (Figure 6f) and TNF-a (Figure 6g)
compared with the control group, whereas the expression
of interferon-g remained unchanged (Figure 6h). Noteworthy,
although secondary bacterial infection leads to a systemic
disease, these results were achieved via intranasal admini-
stration of the inhibitor only. Altogether, our data indicate that
inhibition of MMP-2/9 strongly reduces the bacterial load in
BAL and lung, prevents sepsis and the proinflammatory
response.
DISCUSSION
The resolution of inflammation requires integrated responses
that return damaged tissues to homeostasis. The release of
soluble ectodomains of immune stimulatory receptors by
proteases, which are upregulated during inflammation, is an
effective method of producing anti-inflammatory antagonists
(as proposed for sTREM-1 (ref. 20)). A classic example is the
release of soluble TNF receptor trimers that sequester TNF-a
preventing activation of membrane-bound receptors. Other
examples include shed L-selectin that binds PSGL1 on
endothelial cells curtailing cell adhesion21 and JAM-A that
binds LFA-1 on leukocytes impeding transmigration.22MMP-9
is released during a variety of infections, which we now show is
elevated further upon bacterial super-infection. This additional
production likely reflects the recruitment of large number of
neutrophils containing MMP-9 in pre-formed granules.23,24
MMP-9 promotes endothelial permeability, assists inflamma-
tory cell migration through the breakdown of vascular
basement membranes and extracellular matrix29 and is
associated with the release of membrane-anchored signaling
molecules in response to different stimuli. For example, MMP-
9 activates the inactive form of TGF-b and IL-1b30 via cleavage.
Some cleaved ectodomains are inert or have advantageous
biological activity.31 Others may, however, contribute to the
pathological process. During chronic Staphylococcus aureus
lung infection the activation of ADAM10 cleaves epidermal
growth factor stimulatingmucus production that contributes to
airway obstruction. Genome-wide association studies implicate
ADAM33 in asthma and airway hyper-reactivity and TGF-b
causes ectodomain shedding of ADAM33 that contributes to
lung remodeling. Furthermore, MMP-7 increases ectodomain
shedding of E-cadherin from epithelia, leading to loss of
epithelial coherence.32
We now show TREM-1 cleavage by MMP-9, similar to that
reported for peritoneal and RAW macrophages in vitro,33 and
that MMP-9 inhibition restores neutrophil membrane TREM-
1 expression. Interestingly, MMP-9 also cleaves surfactant
protein D decreasing its ability to aggregate bacteria and
facilitate phagocytosis by alveolarmacrophages.34 This suggests
that MMP-9 inhibition would restore a number of neutrophil
anti-bacterial mechanisms. Definitive proof of a direct effect of
MMP-9 on TREM-1 cleavage is difficult to obtain however, and
would require generating a knockin of TREM-1 expressing a
mutated MMP-9 cleavage site. Although in vivo MMP-2/9
neutralisation would suggest other mechanisms are not
involved with TREM-1 cleavage, we cannot rule out a role
Figure 3 Triggering receptor expressed on myeloid cells-1 (TREM-1)
regulates neutrophil degranulation and integrin expression. Flow
cytometric analysis of cell surface CD63 (LAMP3) (a,c) and CD11b (b,d)
on bone marrow neutrophils pre-incubated with 10 mgml1 control goat
IgG or 10mgml 1 activating TREM-1 antibody (a,b) and 1 mgml1 control
peptide or 1mgml 1 LP17peptide (c,d), followed by stimulationwith 10 nM
fMLP for up to 15min. Data are presented as the mean±s.e.m. of four
mice per group.
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Figure 4 Inhibition of matrix metalloproteinase (MMP)-2/9 reduces the expression of MMP-9 and soluble triggering receptor expressed on myeloid
cells-1 (sTREM-1) during secondary bacterial superinfection. Murine bone-marrow-derived neutrophils incubated with p-aminophenylmercuric acetate
(APMA), unactivated (Pro) MMP-9 and APMA-activated MMP-9. sTREM-1 expression measured by enzyme-linked immunosorbent assay (ELISA) in
cell culture supernatants (bars) and expression of TREM-1 on neutrophils determined by FACS (line) (a). Data are from three independent experiments.
BALB/c mice were infected with 7 PFU of PR8 influenza A virus, followed by 106 CFU S. pneumoniae on day 7 and analyzed 24 h post-S. pneumoniae
infection. On day 6 and on the day of S. pneumoniae infection an MMP-2/9 inhibitor was administered i.n. (100 mg) or vehicle alone (b). Gelantine
zymogram ofMMP-9 activity (c). Expression of sTREM-1 in bronchoalveolar lavage (BAL) (d), serum (e), MMP-9 in BAL (f) and serum (g) andMMP-2 in
BAL (h) determined by enzyme-linked immunosorbent assay (ELISA). Spearman Rank correlation between CFU and sTREM-1 (i) and MMP-9 (j). Data
are expressed asmean±s.e.m., n¼ 6–10mice per group from two independent experiments. Statistical significancewas determined byMann–Whitney
U-test between relevant groups, **Po0.01, ***Po0.001.
Figure 5 Inhibition of matrix metalloproteinase (MMP)-2/9 increases the expression of triggering receptor expressed on myeloid cells-1 (TREM-1) on
neutrophils in the lung during secondary bacterial superinfection. BALB/c mice were treated according to Figure 4b. Total live cells in bronchoalveolar
lavage (BAL) (a) and lung (b) was determined by trypan blue exclusion. Percentage (c) and total numbers (d) of TREM-1 expressing neutrophils in BAL
and percentage (e) and total numbers (f) of TREM-1 expressing neutrophils in the lung was determined by FCM. Correlation between soluble TREM-1
(sTREM-1; gray bars) measured by enzyme-linked immunosorbent assay (ELISA) compared with total neutrophils (&) in the BAL (g) and lung (h). Data
are expressed asmean±s.e.m., n¼ 6–10mice per group from two independent experiments. Statistical significancewas determined byMann–Whitney
U-test between relevant groups, *Po0.05, ***Po0.001.
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for other proteases. Compelling associations combined with
in vivo and in vitro studies however indicate a classic feedback
loop curtailing neutrophil function that has deleterious effects
on subsequent bacterial control.
Although cleavage of activation receptor ectodomains
affords resolution, the timing of this cleavage is crucial, since
early release will allow remaining pathogens to escape and
ultimately lead to prolonged and exaggerated inflammation.
Indeed, blockage of TREM-1 signaling causes severe proin-
flammatory responses to Streptococcus suis, whereas activation
has the opposite effect.35 Similarly agonistic TREM-1 anti-
bodies facilitate early clearance of S. pneumoniae single
infection.7 We now additionally show that TREM-1 facilitates
neutrophil degranulation and hence bactericidal activity.
Inflammation can therefore arise in the presence and absence
of membrane TREM-1. Intact membrane bound TREM-1
slows the resolution of inflammation, whereas once cleaved
bacteria grow exponentially leading to more immune stimula-
tion. The timing of membrane to secreted TREM-1 is therefore
critical. Secondary pulmonary bacterial infections are a feature
of a wide range of lung inflammatory disorders (including
asthma, COPD, cystic fibrosis and IPF) that are also associated
with increased MMP-9 production. The link to soluble
TREM-1, however, has not previously been investigated.
In general the outcome depends on whether TREM-1 is
neutralized or the gene deleted. Neutralization of TREM-1
attenuates inflammation, preventing experimentally induced
bacterial septic shock36–42 and attenuating disease severity in
mice infected with Leishmania major, influenza virus and
Legionella pneumophila.43 However, the situation for Klebsiella
pneumoniae appears to be different with TREM-1/3-deficient
mice showing impaired host defence,44 similar to that observed
for pneumococcal pneumonia45 and Pseudomonas aeruginosa8
in the same mice. These results are not necessarily contra-
dictory since global knockout affects innate immunity from the
outset, whereas therapeutic neutralisation does not.
Ectodomain cleavage of membrane-bound TREM-1 via
MMP-9 during influenza virus infection associates with
secondary bacterial super-infection that is lethal. Cleavage
of TREM-1 is likely required to prevent influenza virus-
mediated damage, but has the disadvantage of creating a
window of susceptibility to bacteria. Respiratory syncytial virus
also stimulates MMP-9 release from human airway epithelium
and is a biomarker of disease severity inmechanically ventilated
children with respiratory syncytial virus lung infection.46 This
suggests that common processes may be occurring in
respiratory disease, which is important in the absence of
knowing the etiological agent(s). We would propose that
MMP-9 inhibition in those most severely affected by respira-
tory viral infection would restore membrane TREM-1
Figure 6 Inhibition of matrix metalloproteinase (MMP)-2/9 prevents bacterial infiltration and the proinflammatory response during secondary bacterial
superinfection.BALB/cmicewere treatedaccording toFigure 4b. Bodyweightwasmeasured daily and is expressedaspercentageof original bodymass
(a). Viable bacterial colony-forming units (CFU) recovered from the BAL (b), lung tissue (c) and peripheral blood (d) was enumerated on agar. Airway
levels of interleukin (IL)-6 (e), IL-1a (f), tumor necrosis factor (TNF)-a (g) and interferon (IFN)-g (h) were enumerated by enzyme-linked immunosorbent
assay (ELISA). Data are expressed as individual mice and mean±s.e.m., n¼ 6–10 mice per group from two independent experiments. Statistical
significance was determined by Mann–Whitney U-test between relevant groups, *Po0.05, ***Po0.001.
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expression and abolish the lethal synergistic viral–bacterial
disease. However, additional effects of neutralizing these
proteases would need to be taken into consideration.
Considering that MMP-2 and MMP-9 cooperate to cleave
chemokines involved in neutrophil migration,47 particularly
IL-8,48 we were surprised to see little effect of these metallo-
proteinases on neutrophil numbers in the airways of bacterial
super-infected influenza resolvedmice. A partial reductionwas,
however, observed in lung tissue. A previous study of single
influenza virus lung infection inMMP-9 knockoutmice reports
reduced neutrophil migration and disease pathogenesis.49 We
believe the mild effect on airway neutrophilia seen in our study
reflects their over-whelming recruitment in this super-infection
model that masks any subtle effect. It is also interesting that
MMP-2/9 inhibition dramatically reduced the bacterial load,
completely prevented sepsis and subsequently reduced many
proinflammatory cytokines, except interferon-g. This suggests
beneficial effects on both bacterial clearance and immune-
mediated pathology. TNF and IL-6 are dominant innate
responses to bacterial infection whereas interferon-g is likely a
remnant from the T-cell response to the previous viral infection
and less affected by MMP-2/9 inhibition. The restriction of
bacteria from the blood ofMMP-2/9 inhibitor treatedmicemay
reflect reduced effects of metalloproteinases on endothelial
permeability and the destruction of vascular basement
membranes and extracellular matrix.21 Alternatively, our data
of TREM-1 modulation of degranulation suggests that bacteria
are cleared quickly without becoming invasive.
A TREM-1 genetic polymorphism rs2234246 has recently
been described that correlates with susceptibility to septic shock
in the Chinese Han population,50 though the implications of
this for membrane bound and soluble TREM-1 are currently
unclear. Soluble TREM-1 has also been utilized as a biomarker
for disease severity, particularly in pneumonia and septic shock.
Importantly, we show a relative insensitivity of serum soluble
TREM-1 compared with airway lavage, which suggests that
sputummay provide better differentiation of disease status. The
timing of TREM-1 ectodomain shedding is clearly critical to the
outcome of bacterial super-infections. In patients with under-
lying disease, this shedding may already have occurred by the
time bacteria start to expand. Protease imbalance and elevated
MMPs are a hallmark of an array of chronic diseases also
susceptible to bacterial infection. Inhibition of MMP-2/9 is
therefore an interesting and feasible target in order to redress
the inability of innate immunity to respond rapidly.
METHODS
Pathogen stocks. Influenza A Puerto Rico/8/34 H1N1 (PR8), a kind
gift fromProf AndreasWack (National Institute forMedical Research,
Mill Hill, UK), was stored at  80 1C in single-use aliquots. Wild type
S. pneumoniae (serotype 2) strain D39 (NTCC 7466, National
Collection of Type Cultures, London, UK) was a kind gift from Jeremy
Brown (Centre for Respiratory Research, UCL, London, UK). Bacterial
stocks were cultured at 37 1C in 5% CO2 in Todd-Hewitt broth (Sigma,
Dorset, UK) supplemented with 0.5% yeast extract (OXOID, Basing-
stoke, UK) to an OD600 of 0.4 (B1 108 colony-forming units (CFU)/
mL) and stored at  80 1C in 10% glycerol as single-use aliquots.
Secondarybacterialpneumoniamodel. Six- to 8-week old or 17–19 g
female BALB/c mice were purchased fromHarlan Olac (Bicester, UK)
andmaintained in specific pathogen-free conditions at Bio Safety Level
2 in accordance with institutional and UK Home Office guidelines.
Mice were anesthetized and i.n. inoculated with 15 plaque-forming
units (PFU) influenza A virus PR8 strain in 50 ml PBS or PBS alone as
mock control. On day 7 post-viral infection, mice were inoculated i.n.
with S. pneumoniae (106 CFU). Disease severity and weight loss were
monitored daily. Mice were culled 24 h post-bacterial infection by
intraperitoneal injection of 3mg pentobarbitone (Animal Care, York,
UK) and exsanguination by cardiac puncture.
MMP-2/9 inhibitor administration during secondary bacterial
pneumonia. Female BALB/c mice were infected i.n. with PR8
influenza (7 PFU in 50 ml PBS) or PBS alone as control. On day 6, mice
were treated with MMP-2/9 inhibitor I (Calbiochem/Milipore,
Hertfordshire UK,) i.n. (100 mg per mouse in 25 ml) in dimethyl-
sulfoxide (DMSO). On day 7, mice were administered MMP-2/9
inhibitor i.n. (100 mg per mouse in 25 ml) in DMSO or vehicle alone as
control and infected i.n. with S. pneumoniae (106 CFU in 25 ml PBS).
Sample recovery and cell isolation. Mice were sacrificed and blood,
BAL fluid and lung tissue were harvested. For bacterial CFU analysis,
10 ml of sodium heparin were added to 90 ml of blood to prevent
clotting (Leo Pharma, Berkshire, UK). The remaining blood was
collected in serum-separating Microtainer tubes (BD Diagnostics,
Oxford, UK) tubes, left to clot overnight at 4 1C prior to centrifugation
at 8,000 r.p.m. for 5min and stored at  80 1C for future analysis. BAL
was performed by inflation of the lung three times with 0.4ml ice-cold
PBS via an intratracheal cannula. Volume of 100ml were used for CFU
analysis, the remaining BAL fluid was centrifuged at 1,200 r.p.m. for
5min and the supernatant stored at  80 1C. Lung tissuewas chopped,
incubated with 0.14 Wunsch units per ml Liberase (Roche, Welwyn
GardenCity, UK) and 50 mgm 1 DNAse I (Roche) for 30min at 37 1C
and passed through a 70 mM cell strainer. Prior to centrifugation at
1,500 r.p.m. for 5min, 100 ml of lung cell suspensionwere used for CFU
analysis. Red blood cells in BAL and lung cell suspensions were lysed
with ammonium chloride potassium (ACK) buffer (0.15 M ammonium
chloride, 1 M potassium hydrogen carbonate and 0.01mM EDTA,
pH 7.2) for 3mins and washed with RPMI-1640 medium
(PAA, Buckinghamshire, UK) containing 10% v/v foetal calf serum
(FCS; Sigma). Cell viability was assessed by trypan blue exclusion.
Bacterial titres. Bacterial titers in BAL, lung and blood were
determined by counting CFU from serial ten-fold dilutions of bacterial
cell suspensions plated on Columbia blood agar plates supplemented
with 5% defibrinated horse blood (TCS Bioscience, Buckingham, UK)
and incubated for 24 h at 37 1C.
Neutrophil in vitro assay. Murine bone-marrow-derived neutrophils
(2 105 cells) were stimulated with Pro-MMP-9 (1mgml 1; R&D
systems, Abingdon, UK), p-aminophenylmercuric acetate (APMA;
1mM, Sigma), and APMA-activated MMP-9 (1 mgml 1) in RPMI-
1640 with 5% FCS serum at 37 1C for 15min. Pro-MMP-9 was
activated by pre-incubation with 1mM APMA for 2 h at 37 1C.
Expression of TREM-1 on the neutrophils was determined by FACS.
Cell supernatants were collected and frozen at  80 1C prior to
detection of sTREM-1 by enzyme-linked immunosorbent assay
(ELISA).
In some experiments neutrophils were flushed out of bone
marrow with ice-cold PBS and isolated using the neutrophil
isolation kit (Miltenyi Biotec, Bisley, UK) as per the manufacturer
instructions. Neutrophils (100 000) were incubated with 10 mgml 1
anti-TREM-1 antibody, 10 mgml 1 control Goat IgG (both from
R&D, Minneapolis, USA), 1 mgml 1 LP17 (LQVTDSGLYRCVI-
YHPP) or 1 mgml 1 LP17 control peptide (TDSRCVIGLYH-
PPLQVY) (both from Biotrend Chemical, Destin, USA)
for 1 h.51 Neutrophils were then stimulated with 10 nM fMLP (Sigma)
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for 5 and 10min, stained with anti-CD63 and anti-CD11b antibodies
(both from eBioscience, Altrincham, UK) and analyzed by flow
cytometry.
Flow cytometry. Cells isolated from BAL or lung tissue digest were
stained with the live/dead marker Zombie Aqua (Biolegend, London,
UK), Ly6G (eBioscience, Hatfield, UK) and TREM-1 (R&D systems).
Labeled cells were acquired on a BD Fortessa (BD Bioscience) and
analyzed using FlowJo (Treestar, Ashland, OR, USA).
Mediator analysis. Murine sTREM-1, MMP-2 and MMP-9 were
measured by Duoset ELISA kits (R&D systems) and murine IL-6, IL-
1a, TNF-a and interferon-g (eBioscience) ELISA kits according to the
manufacturer’s instructions. MMP-9 activity was determined using
Novex 10% zymogram gelatin gels (Invitrogen, Paisley, UK). Images
were captured and analyzed using myECL Imager software (Thermo-
Scientific, Cheshire, UK).
Statistical analysis. Data were analyzed using Prism 5 (GraphPad
Software, CA, USA). P-values were determined by theMann–Whitney
test comparing between 2 groups and are indicated on graphs as
* Po0.05, **Po0.01, ***Po0.001. Correlations were analyzed using
Spearman’s rank test.
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